Nivolumab is indicated in combination with fluoropyrimidine and platinum-based combination chemotherapy for the first line treatment of adult patients with HER2 negative advanced or metastatic gastric, gastro oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) ≥5.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||01/11/2021|
|Rapid review completed||29/11/2021|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of nivolumab compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by the HSE||07/12/2021|
|Pre-submission consultation with Applicant||Scheduled|
|Current Status||Pre-submission consultation with Applicant scheduled|